The fight against drug-resistant infections has found a new weapon to combat the emerging Candida Auris (C. Auris) disease. Based on preliminary lab results released by Applied UV, Inc. (Applied UV), an infection control technology company utilizing narrow range ultraviolet light (UVC), it has found its proprietary Airocide Air Purification System effective in killing the emerging pathogen.
Additionally, ResInnova Laboratories, an independent microbiology testing lab specializing in antimicrobial technologies, confirmed Applied UV’s devices are capable of reducing C. Auris on sink handles up to 99.99% with just two minutes of operation compared to prior testing on other UV devices that required up to 45 minutes of operation to achieve similar results.
These tests also confirm that Applied UV’s air and surface disinfection systems are effective at killing SARS-CoV-2 (COVID-19) as well.
What is C. Auris?
Caused by a drug-resistant fungus, C. Auris is an infection commonly acquired in hospital settings or long-term care facilities. Inhaled in through the air, the fungus infects patients through the bloodstream, making it capable of traveling through and infecting multiple organs and the central nervous system.
The fact that it is resistant to most readily available drugs makes it exceptionally difficult to handle once an infection takes hold, and makes it a considerable threat in immunocompromised individuals. The Center for Disease Control and Prevention (CDC) has stated that 30-60% of those infected by C. Auris die as a result of bloodstream infection, making it one of the most significant infectious diseases in the world today.
More information regarding fungal diseases and COVID-19 can be found on the CDC website, here, while specific information regarding C. Auris can be found here.
Accelerating the Adoption of Greater Protection Plans
With this round of rigorous testing, Applied UV aims to open greater avenues for commercial adoption of disinfection products while being able to provide broader protection plans against COVID-19, its variants and other emerging pathogenic infections such as C. Auris.
This research, as Applied UV states, is to be able to provide customers with a means of quality assurance. In a market that is often bombarded with advertisements on air purifiers of questionable efficacy and safety, Applied UV hopes to bring greater awareness to effective, affordable solutions, such as its own brand of products, through rigorous research and continued engagement with globally recognized facilities, brand and institutions.